

PG3749USW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Clayton et al.
Intl. Serial No.: 10/049,142 Group Art Unit: 1617
Intl. File Date: February 5, 2002 Examiner: M. Bahar
For: Use of EP4 Receptor Ligands in the Treatment of Neuropathic Pain and Colon Cancer

Director of the U.S. Patent and Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- ☒ Copies of the references are enclosed: 1-6
☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d))
☐ A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.

- A. ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

- ☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

- B. ☐ The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311, whichever occurs first.

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

- ☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

- C. ☒ The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- ☐ The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.

☒ Please charge any required fees to Deposit Account No.07-1392.


☐ A duplicate copy of this paper is attached.

Respectfully Submitted,



Lorie Ann Morgan
Registration No. 38,181

Date: *17 Aug 2004*
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-
Facsimile: (919) 483-7988



FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG3749USW		SERIAL NO. 10/049142	
				APPLICANT: Clayton et al.			
				FILING DATE: February 5, 2002		GROUP 1617	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	1	WO 99/47497	Sept. 23, 1999	WIPO			
	2	WO 00/18405	Apr. 6, 2000	WIPO			
	3	WO 00/20371	Apr. 13, 2000	WIPO			
	4	WO 00/20398	Apr. 13, 2000	WIPO			
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	5	Dumais, N., et al. "Prostaglandin E ₂ Up-Regulates HIV-1 Long Terminal Repeat-Driven Gene Activity in T Cells Via NF- κ B-dependent and -Independent Signaling Pathways." J. Biol. Chem., Vol 273, No. 42, pp. 27306-27314.					
	6	Rufer, C., et al. "New acylated 2-(4-aminophenyl)-propionic acids as anti-inflammatory agents." Eur J. Med. Chem - chim. Ther. (1978), 13(2), 193-8.					
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							